JP2006516533A - アントラサイクリンおよびタキサンによる転移性乳癌の治療 - Google Patents

アントラサイクリンおよびタキサンによる転移性乳癌の治療 Download PDF

Info

Publication number
JP2006516533A
JP2006516533A JP2004533120A JP2004533120A JP2006516533A JP 2006516533 A JP2006516533 A JP 2006516533A JP 2004533120 A JP2004533120 A JP 2004533120A JP 2004533120 A JP2004533120 A JP 2004533120A JP 2006516533 A JP2006516533 A JP 2006516533A
Authority
JP
Japan
Prior art keywords
chemotherapeutic agent
administered
patient
group
diphenyl compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004533120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516533A5 (https=
Inventor
ローン、 ジェイ． ブランデス、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Original Assignee
University of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manitoba filed Critical University of Manitoba
Publication of JP2006516533A publication Critical patent/JP2006516533A/ja
Publication of JP2006516533A5 publication Critical patent/JP2006516533A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004533120A 2002-09-04 2003-09-03 アントラサイクリンおよびタキサンによる転移性乳癌の治療 Withdrawn JP2006516533A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40767902P 2002-09-04 2002-09-04
PCT/CA2003/001340 WO2004022040A2 (en) 2002-09-04 2003-09-03 Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist

Publications (2)

Publication Number Publication Date
JP2006516533A true JP2006516533A (ja) 2006-07-06
JP2006516533A5 JP2006516533A5 (https=) 2006-10-19

Family

ID=31978506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004533120A Withdrawn JP2006516533A (ja) 2002-09-04 2003-09-03 アントラサイクリンおよびタキサンによる転移性乳癌の治療

Country Status (11)

Country Link
US (1) US20060089317A1 (https=)
EP (1) EP1536779A2 (https=)
JP (1) JP2006516533A (https=)
KR (1) KR20050086415A (https=)
CN (1) CN1694691A (https=)
AU (1) AU2003266047A1 (https=)
BR (1) BR0314097A (https=)
CA (1) CA2497180A1 (https=)
MX (1) MXPA05002465A (https=)
RU (1) RU2005109421A (https=)
WO (1) WO2004022040A2 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2063574T3 (es) * 1990-12-17 1995-01-01 Univ Manitoba Metodo de tratamiento mejorado para el cancer.
GB9303210D0 (en) * 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
PL369792A1 (en) * 2001-11-01 2005-05-02 Ym Biosciences, Inc. Use of n,n-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (dppe) in cancer therapy
US20050119263A1 (en) * 2001-11-09 2005-06-02 Vincent Mark D. Treatment of breast cancer

Also Published As

Publication number Publication date
EP1536779A2 (en) 2005-06-08
KR20050086415A (ko) 2005-08-30
AU2003266047A8 (en) 2004-03-29
WO2004022040A2 (en) 2004-03-18
BR0314097A (pt) 2005-07-19
CN1694691A (zh) 2005-11-09
AU2003266047A1 (en) 2004-03-29
CA2497180A1 (en) 2004-03-18
MXPA05002465A (es) 2005-12-14
RU2005109421A (ru) 2005-10-20
WO2004022040A3 (en) 2004-04-29
US20060089317A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
RU2321396C2 (ru) Применение доцетаксела/доксорубицина/циклофосфамида во вспомогательной терапии рака молочной железы и яичников
JP2001247459A (ja) 癌の組み合わせ療法
JP2007511498A (ja) Ｅｔ−７４３とドキソルビシンとを使用することを含むガンの併用療法
JP2009536956A (ja) 抗癌治療法
JP2007511509A (ja) Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
EP1206256B1 (en) Combination therapy using pentafluorobenzenesulfonamide and platin compound
JP2000505796A (ja) エダトレキセートおよびタキサン誘導体（例えばパクリタキセル）を用いる癌を処置するための組み合わせ治療方法
JP2006516533A (ja) アントラサイクリンおよびタキサンによる転移性乳癌の治療
EP1545709B1 (en) Neoadjuvant treatment of breast cancer
JP2005512996A (ja) 乳癌の治療
AU2018205735A1 (en) Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
JP2007523825A (ja) 乳癌治療のためのｄｐｐｅと他の化学療法剤との併用
JPH09506902A (ja) 前立線癌の化学療法剤の補助剤
WO2004022044A1 (en) Use of a combination of a taxane with dppe for the treatment of cancer
JP2006516532A5 (https=)
JP2006516533A5 (https=)
KR20110104932A (ko) Ａｖｅ８０６２ 및 도세탁셀이 조합된 항종양 조합물
EP1599210A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
AU2002340668A1 (en) Treatment of breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060904

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20071206